You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君实生物-B(01877.HK)预计一季度营业收入同比增长89.69%-152.92%
格隆汇 03-19 22:32

格隆汇3月19日丨君实生物-B(01877.HK)公布,截至2020年3月31日止3个月,预计公司实现营业收入1.5亿-2亿元,同比增长89.69%-152.92%;归属于公司普通股股东的净亏损1.98亿-2.33亿元,同比扩大37.10%-46.45%。

2020年一季度公司收入预计同比去年同期增幅较大,主要原因为:公司产品"特瑞普利单抗"于2018年12月正式获得国家药品监督管理局有条件批准上市并于2019年2月末起开展销售,凭藉市场先发优势、良好的产品临床疗效、产品价格优势、经验丰富的销售团队、高效的销售组织体系建设和符合产品特性的市场推广方案,预计公司2020年一季度收入较2019年一季度增幅较大。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account